Business
Celcuity Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Announced a clinical trial collaboration in December with Massachusetts General Hospital, UCLA, and Vanderbilt and Puma Biotechnology to conduct a Phase II
About this update from Celcuity Inc.
[{"type":"text","content":"Announced a clinical trial collaboration in December with Massachusetts General Hospital, UCLA, and Vanderbilt and Puma Biotechnology to conduct a Phase II clinical trial.In January, announced a clinical trial collaboration with Sarah Cannon Research Institute and Pfizer Inc. to conduct a Phase II clinical trial.Additional clinical trial collaborations with major pharmaceutical companies are expected to be announced in the first half of 2021.MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the fourth quarter and year ended December 31, 2020 and summarized recent business progress.\"We built momentum in our business over the past few months, signing additional clinical trial agreements to collaborate with several major cancer research centers and pharmaceutical companies while advancing additional new CELsignia tests. In December, we announced a collaboration with Massachusetts General Hospital, UCLA, Vanderbilt, and Puma Biotechnology for a Phase II trial to evaluate the safety and efficacy of Puma's drug, Nerlynx, and AstraZeneca's drug, Faslodex,\" said Brian Sullivan, Chairman and Chief Executive Officer of Celcuity.\"Last month, we announced another clinical trial collaboration, our fourth one, with Sarah Cannon Research Institute and Pfizer, Inc., for a Phase II trial that will evaluate the efficacy and safety of two Pfizer targeted therapies, VIZIMPRO®, a pan-HER inhibitor, and XALKORI®, a c-Met inhibitor. Both of these recent collaborations aim to address a significant unmet need for new treatment options for metastatic HER2- breast cancer patients whose disease progressed on prior therapies.\"Additional collaboration discussions with pharmaceutical companies also progressed despite the headwinds from COVID-19. We remain confident we will finalize new clinical trial collaborations in the first half of 2021. Finally, although our FACT-1 and FACT-2 trials were somewhat impacted by COVID-19 related delays in recent months, we still expect interim results from these trials in the latter half of 2021 or early 2022.\"Recent Highlights and Upcoming MilestonesAnnounced two new clinical trial collab...